| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
119,920,000 |
| Market
Cap: |
2.50(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.96 - $32.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
97,498 |
194,989 |
250,525 |
524,601 |
| Total Sell Value |
$1,990,812 |
$3,814,194 |
$5,260,505 |
$13,449,119 |
| Total People Sold |
2 |
5 |
5 |
6 |
| Total Sell Transactions |
4 |
19 |
37 |
75 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schuth Alexander O. |
COO and Secretary |
• – – |
2021-10-04 |
4 |
AS |
$50.24 |
$505,605 |
I/I |
(10,000) |
473,083 |
|
-31% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2021-10-01 |
4 |
AS |
$49.38 |
$923,550 |
I/I |
(18,333) |
2,140,034 |
|
-32% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2021-09-20 |
4 |
OE |
$0.68 |
$6,151 |
D/D |
9,045 |
95,499 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2021-09-15 |
4 |
AS |
$52.28 |
$88,969 |
D/D |
(1,666) |
129,499 |
|
-37% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2021-09-07 |
4 |
AS |
$54.70 |
$555,485 |
I/I |
(10,000) |
474,038 |
|
-42% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2021-09-01 |
4 |
AS |
$54.27 |
$1,002,012 |
I/I |
(18,333) |
2,158,367 |
|
-30% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2021-08-23 |
4 |
AS |
$48.91 |
$300,454 |
I/I |
(6,143) |
158,630 |
|
-9% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2021-08-19 |
4 |
S |
$49.56 |
$126,186 |
I/I |
(2,544) |
484,038 |
|
7% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2021-08-19 |
4 |
S |
$49.38 |
$117,769 |
I/I |
(2,376) |
2,176,700 |
|
7% |
|
| Ho Carole |
Chief Medical Officer |
• – – |
2021-08-19 |
4 |
S |
$49.31 |
$126,230 |
I/I |
(2,546) |
164,773 |
|
7% |
|
| Krognes Steve E. |
CFO and Treasurer |
• – – |
2021-08-19 |
4 |
S |
$49.52 |
$113,263 |
D/D |
(2,285) |
95,302 |
|
7% |
|
| Sato Vicki L |
Director |
– • – |
2021-08-18 |
4 |
AS |
$51.26 |
$86,139 |
D/D |
(1,666) |
131,165 |
|
-13% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2021-08-04 |
4 |
AS |
$51.52 |
$522,233 |
I/I |
(10,000) |
481,582 |
|
-10% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2021-08-02 |
4 |
AS |
$50.80 |
$942,477 |
I/I |
(18,333) |
2,174,076 |
|
-12% |
|
| Sato Vicki L |
Director |
– • – |
2021-07-21 |
4 |
AS |
$64.25 |
$108,510 |
D/D |
(1,666) |
132,831 |
|
-31% |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2021-07-06 |
4 |
AS |
$76.20 |
$762,040 |
I/I |
(10,000) |
491,582 |
|
-33% |
|
| Watts Ryan J. |
President and CEO |
• • – |
2021-07-01 |
4 |
AS |
$76.38 |
$1,416,300 |
I/I |
(18,333) |
2,192,409 |
|
-31% |
|
| Sato Vicki L |
Director |
– • – |
2021-06-23 |
4 |
AS |
$70.20 |
$117,845 |
D/D |
(1,666) |
134,497 |
|
-32% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2021-06-07 |
4 |
AS |
$70.35 |
$6,639,523 |
D/D |
(94,378) |
2,544,370 |
|
-38% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2021-06-07 |
4 |
OE |
$18.00 |
$1,765,275 |
D/D |
94,378 |
2,638,748 |
|
- |
|
| Schuth Alexander O. |
COO and Secretary |
• – – |
2021-06-04 |
4 |
AS |
$64.35 |
$645,500 |
I/I |
(10,000) |
501,582 |
|
-30% |
|
| Schenkein David P |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
5,327 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
5,327 |
|
- |
|
| Nelsen Robert |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
12,432 |
|
- |
|
| Klein Peter S |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
5,327 |
|
- |
|
416 Records found
|
|
Page 7 of 17 |
|
|
1.11 (5.62%) 
